Life Edit Therapeutics
Drew Kelso currently serves as Associate Director and previously held roles as Senior Scientist and Scientist II at Life Edit Therapeutics since June 2021, focusing on DNA repair factors in genome maintenance as potential cancer therapeutic targets. Prior experience includes a Scientist role at Intellia Therapeutics, a Postdoctoral Research Fellow at City of Hope, and an Adjunct Professor position at Azusa Pacific University teaching General Biology I Laboratory. Drew also contributed as a Project Consultant at ChromoLogic, a Graduate Research Assistant at Clemson University, and a Laboratory Technician at LabCorp, among other roles. Drew holds a PhD in Biochemistry and Molecular Biology from Clemson University, a Certificate in Bioscience Management from Keck Graduate Institute, an MS in Biotechnology from the University of Alabama at Birmingham, and a BS in Biology from the University of Montevallo.
Life Edit Therapeutics
Life Edit, an ElevateBio company, is a next-generation genome editing company that has built a highly innovative platform with one of the world’s largest and most diverse collections of novel RNA-guided nucleases (RGNs) and base editors. The platform allows Life Edit to target any genomic sequence and develop novel human therapeutics for the most challenging genetic diseases by enabling ex vivo engineering for cell therapies and regenerative medicines and in vivo delivery of gene therapies. In addition to developing its own pipeline of cell and gene therapies, Life Edit Therapeutics will continue to strengthen its platform of genome-editing enzymes, provide gene-editing expertise to strategic partners, and form other third-party partnerships to discover and develop new therapies.